Myeloma Patients Europe will be present at the 56th American Society of Hematology Annual Meeting, to be held in San Francisco betweeb 6 and 9 December.
Over 20.000 people from all arround the globe will attend the largest hematology event in the world. Hundreds of sessions, posters and exhibits will bring together, not only hematologists, but also other stakeholders, such as non-clinical researchers, nurses, industry and, of course, patients. Continue reading
The Oncologic Drugs Advisory Committee (ODAC), a board of the US Food and Drug Administration (FDA), voted 5 to 2 against the approval recommendation of panobinostat in combination with bortezomib and dexamethasone in multiple myeloma patients who have received at least one prior therapy. Continue reading
Myeloma Patients Europe is currently developing a European Atlas of Access to Myeloma Treatment.
Access to treatment across Europe is extremely variable. Patient group advocacy can make a huge difference in improving access, but often doesn’t have the evidence, knowledge and tools to advocate effectively. Continue reading
Authors: Heinz Ludwig, Pieter Sonneveld, Faith Davies, Joan Bladé, Mario Boccadoro, Michele Cavo, Gareth Morgan, Javier de la Rubia, Michel Delforge, Meletios Dimopoulos, Hermann Einsele, Thierry Facon, Hartmut Goldschmidt, Philippe Moreau, Hareth Nahi, Torben Plesner, Jesús San-Miguel, Roman Hajek, Pia Sondergeld and Antonio Palumbo.
The treatment of multiple myeloma has undergone significant changes and has resulted in the achievement of molecular remissions,the prolongationof remission duration,and extended survival becoming realistic goals, with a cure being possible in a small but growing numberof patients. Continue reading
For yet another year, Myeloma Patients Europe will be present at the European Society for Medical Oncology Congress. The event will take place in Madrid between the 26 to 30 of September.
The main congress of European Oncology is expected to meet over 16.000 attendees from over 120 countries. ESMO 2014 intends to merge state-of-the-art oncology with the latest breakthrough discoveries, from cost-effective anti-cancer treatments to best supportive care. Continue reading
The MPE Member Update is a bi-monthly summary of the activities undertaken by MPE members. It inlcudes updates on the projects and activities they have been involved in over the last two month and their plans for the nearer future.
The September issue of the MPE Member Update has just been published. To check the updates by member group, please click here.
If you wish to subscribe to the MPE Member Update or the MPE Newsletter, please send an email to firstname.lastname@example.org.
Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled eff ectiveness trial for the SMaRT (Symptom Management Research Trials) Oncology-2
Michael Sharpe, Jane Walker, Christian Holm Hansen, Paul Martin, Stefan Symeonides, Charlie Gourley, Lucy Wall, David Weller, Gordon Murray, Continue reading
AMGEN ANNOUNCES TOP-LINE RESULTS FROM Phase 3 FOCUS TRIAL of KYPROLIS® IN PATIENTS WITH RELAPSED AND ADVANCED REFRACTORY MULTIPLE MYELOMA
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. (Aug. 13, 2014) – Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS) (HR=0.975, 95 percent CI, 0.760, 1.249). The 315-patient, open-label study evaluated single-agent Kyprolis® (carfilzomib) for Injection compared to an active control regimen of low-dose dexamethasone, or equivalent corticosteroids, plus optional cyclophosphamide in patients with relapsed and advanced refractory multiple myeloma. Nearly all patients in the control arm received cyclophosphamide. Patients were heavily pretreated and had received a median of five therapeutic regimens prior to study entry.
Value in Health, Volume 17, Issue 4, Pages 471-475, June 2014
Authors:C. Daniel Mullins, PhD; Joseph Vandigo, MBA; Zhiyuan Zheng, PhD; Paul Wicks, PhD
To view the article, please click here.
The European Cancer Patient’s Bill of Rights will be launched at the European Parliament in Strasbourg on 4 February 2014, coinciding with the World Cancer Day.
The launch is hosted by the European Cancer Concord (ECC) and European Cancer Patient Coalition (ECPC) in association with the Members of the European Parliament Against Cancer (MAC) Group. Continue reading